Hong Kong · Delayed Price · Currency is HKD Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of HKD 65.28 billion. The enterprise value is 145.82 billion.
| Market Cap | 65.28B |
| Enterprise Value | 145.82B |
Important Dates
The last earnings date was Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | Jun 23, 2026 |
Share Statistics
Sinopharm Group has 3.12 billion shares outstanding. The number of shares has decreased by -0.36% in one year.
| Current Share Class | 1.34B |
| Shares Outstanding | 3.12B |
| Shares Change (YoY) | -0.36% |
| Shares Change (QoQ) | -82.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 28.75% |
| Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 8.20 and the forward PE ratio is 7.32. Sinopharm Group's PEG ratio is 1.82.
| PE Ratio | 8.20 |
| Forward PE | 7.32 |
| PS Ratio | 0.10 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | 4.80 |
| P/OCF Ratio | 4.15 |
| PEG Ratio | 1.82 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.76, with an EV/FCF ratio of 10.72.
| EV / Earnings | 18.31 |
| EV / Sales | 0.23 |
| EV / EBITDA | 5.76 |
| EV / EBIT | 7.10 |
| EV / FCF | 10.72 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.53.
| Current Ratio | 1.41 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | 3.30 |
| Debt / FCF | 5.81 |
| Interest Coverage | 7.51 |
Financial Efficiency
Return on equity (ROE) is 8.31% and return on invested capital (ROIC) is 7.13%.
| Return on Equity (ROE) | 8.31% |
| Return on Assets (ROA) | 2.75% |
| Return on Invested Capital (ROIC) | 7.13% |
| Return on Capital Employed (ROCE) | 12.00% |
| Weighted Average Cost of Capital (WACC) | 4.71% |
| Revenue Per Employee | 6.74M |
| Profits Per Employee | 83,893 |
| Employee Count | 108,217 |
| Asset Turnover | 1.47 |
| Inventory Turnover | 8.49 |
Taxes
In the past 12 months, Sinopharm Group has paid 4.41 billion in taxes.
| Income Tax | 4.41B |
| Effective Tax Rate | 26.79% |
Stock Price Statistics
The stock price has increased by +14.32% in the last 52 weeks. The beta is 0.60, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +14.32% |
| 50-Day Moving Average | 20.93 |
| 200-Day Moving Average | 19.73 |
| Relative Strength Index (RSI) | 53.73 |
| Average Volume (20 Days) | 5,749,313 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of HKD 640.05 billion and earned 7.96 billion in profits. Earnings per share was 2.55.
| Revenue | 640.05B |
| Gross Profit | 46.37B |
| Operating Income | 19.17B |
| Pretax Income | 16.47B |
| Net Income | 7.96B |
| EBITDA | 21.69B |
| EBIT | 19.17B |
| Earnings Per Share (EPS) | 2.55 |
Balance Sheet
The company has 54.30 billion in cash and 78.97 billion in debt, with a net cash position of -24.66 billion or -7.90 per share.
| Cash & Cash Equivalents | 54.30B |
| Total Debt | 78.97B |
| Net Cash | -24.66B |
| Net Cash Per Share | -7.90 |
| Equity (Book Value) | 149.29B |
| Book Value Per Share | 29.94 |
| Working Capital | 111.36B |
Cash Flow
In the last 12 months, operating cash flow was 15.73 billion and capital expenditures -2.13 billion, giving a free cash flow of 13.60 billion.
| Operating Cash Flow | 15.73B |
| Capital Expenditures | -2.13B |
| Depreciation & Amortization | 2.51B |
| Net Borrowing | -21.63B |
| Free Cash Flow | 13.60B |
| FCF Per Share | 4.36 |
Margins
Gross margin is 7.25%, with operating and profit margins of 3.00% and 1.24%.
| Gross Margin | 7.25% |
| Operating Margin | 3.00% |
| Pretax Margin | 2.57% |
| Profit Margin | 1.24% |
| EBITDA Margin | 3.39% |
| EBIT Margin | 3.00% |
| FCF Margin | 2.12% |
Dividends & Yields
This stock pays an annual dividend of 0.79, which amounts to a dividend yield of 3.75%.
| Dividend Per Share | 0.79 |
| Dividend Yield | 3.75% |
| Dividend Growth (YoY) | -22.70% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.36% |
| Shareholder Yield | 4.11% |
| Earnings Yield | 12.20% |
| FCF Yield | 20.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.27 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.27 |
| Piotroski F-Score | 4 |